why choose us

First received: November 13, 2023

Clinical Trial: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Moderate to Severe Atopic Dermatitis

Study Type: INTERVENTIONAL


Official Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Seve

Brief Summary: This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis.The estimated duration is 15-35 days for screening and then up to approximately day 378 (last dose on day 280 + 98 days safety follow-up) for all patients.Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance…

Read more